1. Home
  2. IGMS vs IVCA Comparison

IGMS vs IVCA Comparison

Compare IGMS & IVCA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • IGMS
  • IVCA
  • Stock Information
  • Founded
  • IGMS 1993
  • IVCA 2021
  • Country
  • IGMS United States
  • IVCA Cayman Islands
  • Employees
  • IGMS N/A
  • IVCA N/A
  • Industry
  • IGMS Biotechnology: Pharmaceutical Preparations
  • IVCA Blank Checks
  • Sector
  • IGMS Health Care
  • IVCA Finance
  • Exchange
  • IGMS Nasdaq
  • IVCA Nasdaq
  • Market Cap
  • IGMS 82.1M
  • IVCA 95.3M
  • IPO Year
  • IGMS 2019
  • IVCA 2022
  • Fundamental
  • Price
  • IGMS $1.24
  • IVCA $12.04
  • Analyst Decision
  • IGMS Hold
  • IVCA
  • Analyst Count
  • IGMS 8
  • IVCA 0
  • Target Price
  • IGMS $6.14
  • IVCA N/A
  • AVG Volume (30 Days)
  • IGMS 198.4K
  • IVCA 1.8K
  • Earning Date
  • IGMS 03-06-2025
  • IVCA 01-01-0001
  • Dividend Yield
  • IGMS N/A
  • IVCA N/A
  • EPS Growth
  • IGMS N/A
  • IVCA N/A
  • EPS
  • IGMS N/A
  • IVCA 0.26
  • Revenue
  • IGMS $2,679,000.00
  • IVCA N/A
  • Revenue This Year
  • IGMS $134.71
  • IVCA N/A
  • Revenue Next Year
  • IGMS $74.27
  • IVCA N/A
  • P/E Ratio
  • IGMS N/A
  • IVCA $46.73
  • Revenue Growth
  • IGMS 25.77
  • IVCA N/A
  • 52 Week Low
  • IGMS $1.15
  • IVCA $11.19
  • 52 Week High
  • IGMS $22.50
  • IVCA $12.37
  • Technical
  • Relative Strength Index (RSI)
  • IGMS 37.38
  • IVCA 67.77
  • Support Level
  • IGMS $1.17
  • IVCA $11.82
  • Resistance Level
  • IGMS $1.31
  • IVCA $12.00
  • Average True Range (ATR)
  • IGMS 0.09
  • IVCA 0.03
  • MACD
  • IGMS 0.05
  • IVCA 0.00
  • Stochastic Oscillator
  • IGMS 32.14
  • IVCA 100.00

About IGMS IGM Biosciences Inc.

IGM Biosciences Inc is a biotechnology company engaged in the development of IgM antibody therapeutics for the treatment of cancer, infectious diseases, and autoimmune and inflammatory diseases. Its IgM antibody technology platform is suited for developing T cell engagers, receptor cross-linking agonists, and targeted cytokines. Its product candidate, Aplitabart: An IgM antibody targeting Death Receptor 5 (DR5) proteins, for the treatment of colorectal cancer; Imvotamab: A bispecific for severe systemic lupus erythematosus (SLE) and one for severe rheumatoid arthritis (RA); and IGM-2644: A bispecific T cell engaging IgM antibody targeting CD38 and CD3 proteins, currently planned for evaluation in autoimmune disease.

About IVCA Investcorp India Acquisition Corp.

Investcorp AI Acquisition Corp is a blank check company.

Share on Social Networks: